新春寄语 美敦力全球高级副总裁及 大中华区总裁 顾宇韶 推荐阅读： 自 1989年进入中国市场，美敦力深耕三十六载，走过了从"引进来"、"走出去"到"立得稳"的发展历程，美敦 力在时代浪潮中也不断进阶，从最初的技术输入者，成长为与中国医疗行业共创共赢的生态伙伴。围绕"全球 创新本土化，中国创新全球化"的战略方向，美敦力持续推进数智化与本土全价值链的深度融合，覆盖研发、 生产、销售、培训、售后及投资等关键环节，不断夯实在华发展的长期根基。 2025年，当中国人工智能浪潮加速奔涌，美敦力也聚焦数智医疗创新，不断升级本土价值链布局，致力于扩大与优 质医疗服务的可及，并取得了一系列标志性进展。10月，美敦力在华首个数字化医疗创新地落地北京，聚焦人工智 能和大数据驱动的疾病管理解决方案，同时建设高水平的医疗培训中心、打造患者关爱中心、特别设有美敦力博物 馆，助力构建本土智慧化、普惠化的医疗体系，期望成为连接全球创新力量与中国本土生态伙伴的关键枢纽。 依托上海、成都双创新中心，美敦力累计实现超过 25 万人次的医疗专业培训，支持中国临床能力提升。我们连续 8 年全勤参与进博会、首次亮相链博会，积极参与国家级开放交流盛事。 ...

Market Overview - The Uterine Fibroid Market was valued at USD 5.26 Billion in 2025 and is projected to reach USD 9.43 Billion by 2033, growing at a CAGR of 7.63% from 2026 to 2033 [1][8]. Growth Drivers - The market is expanding due to the increased incidence of uterine fibroids among women of childbearing age, with approximately 70 to 80% of women experiencing fibroids by age 50 [2]. - Rising healthcare infrastructure in emerging markets and increased awareness regarding fibroid treatment options are also contributing to market growth [5]. Treatment Trends - There is a significant trend towards minimally invasive techniques for treating uterine fibroids, with adoption rates rising by over 60% in the past five years [4]. - Minimally invasive procedures are expected to grow at the fastest CAGR of 8.63% from 2026 to 2033, driven by advancements in technology and patient preference for less invasive options [11]. Market Segmentation - By Type: Submucosal Fibroids dominated with 36.24% in 2025, while Intramural Fibroids are expected to grow at the fastest CAGR of 8.20% from 2026 to 2033 [9][10]. - By Treatment Type: Surgical Procedures held 38.45% in 2025, with Minimally Invasive Procedures projected to grow at 8.63% CAGR [11]. - By Technology: Laparoscopic Surgery accounted for 36.58% in 2025, with MRI-Guided Focused Ultrasound expected to grow at 8.83% CAGR [12]. - By End-User: Hospitals & Clinics dominated with 47.49% in 2025, while Ambulatory Surgical Centers are expected to grow at 8.43% CAGR [13]. Regional Insights - The U.S. Uterine Fibroid Market was valued at USD 1.78 Billion in 2025 and is projected to reach USD 3.11 Billion by 2033, growing at a CAGR of 7.25% [14]. - North America is expected to hold a 45.32% market share in 2025, while Asia Pacific is anticipated to grow at the fastest CAGR from 2026 to 2033 [15]. Recent Developments - In January 2024, Pfizer Canada announced the availability of MYFEMBREE® for treating uterine fibroids and endometriosis [17]. - In September 2024, Theramex announced the first commercial sale of Yselty® in Germany, marking a new treatment option for women with moderate to severe symptoms of uterine fibroids [17].

Group 1 - Walmart is set to report earnings pre-market next Thursday, leading a busy earnings week with over 40 companies reporting on Tuesday and Wednesday [1] - The upcoming earnings reports include significant players from the healthcare sector, such as Medtronic plc, and the tech sector with Palo Alto Networks Inc [1] - The week concludes with Enbridge Inc, a leader in the energy sector, reporting on Friday morning [1]

Core Viewpoint - The article emphasizes the author's extensive experience in the investment field, particularly in analytics and accounting, highlighting a personal interest in dividend investing [1]. Group 1 - The author holds a master's degree in Analytics from Northwestern University and a bachelor's degree in Accounting [1]. - The author has over 10 years of experience in the investment arena, starting as an analyst and progressing to a management role [1]. - Dividend investing is mentioned as a personal hobby, indicating a focus on income-generating investments [1].

Core Insights - Medtronic plc (NYSE:MDT) is recognized as one of the 13 Cheapest Dividend Aristocrats to invest in [1] Group 1: Analyst Upgrades and Market Potential - Needham & Company upgraded Medtronic from Hold to Buy, setting a price target of $121, citing early-phase product rollouts targeting multi-billion dollar markets that are expected to accelerate revenue growth [2] - The new products are projected to contribute over 1% to Medtronic's overall organic revenue growth, with expectations that Elliott Management's involvement will enhance execution, organic growth, and profitability [2] Group 2: Acquisition Strategy - Medtronic plans to acquire CathWorks for up to $585 million to expand its heart devices portfolio, which currently generates nearly 40% of its revenue [3] - The acquisition includes CathWorks' FFRangio System, a non-invasive diagnostic platform for coronary artery disease, further strengthening Medtronic's position in data-driven cardiac care [3] - The transaction is based on a partnership formed in 2022 and is subject to US regulatory approval, with an expected closing by the end of fiscal 2026 [4]

Core Insights - Medtronic has received FDA clearance for the Stealth AXiS™ surgical system, which integrates planning, navigation, and robotics for spine surgery, marking a significant advancement in surgical technology [1] Company Overview - Medtronic is a global leader in healthcare technology, headquartered in Galway, Ireland, with over 95,000 employees across more than 150 countries [1] - The company aims to alleviate pain, restore health, and extend life through innovative technologies that address various health conditions [1] Product Details - The Stealth AXiS™ system is designed for spine procedures and has an architecture that supports future cranial and ENT applications, pending further FDA clearance [1] - This system combines familiar navigation workflows with a modular robotic design, allowing for flexibility in deployment according to clinical needs [1] Technological Innovations - A key feature of the Stealth AXiS™ system is LiveAlign™ segmental tracking, which provides real-time visualization of anatomic motion and surgical adjustments, reducing the need for repeated imaging [1] - The system is part of Medtronic's AiBLE™ smart ecosystem, facilitating a seamless flow of information across the surgical continuum [1] Market Position - Medtronic's Cranial and Spinal Technologies division serves over 4 million patients annually with a portfolio of 150 products addressing more than 20 pathologies [1] - The company focuses on building durable platforms that simplify surgical workflows while enabling future expansions across various procedures and specialties [1]

Earnings Report - Medtronic plc is set to release its third-quarter earnings on February 17, with analysts expecting earnings of $1.34 per share, a decrease from $1.39 per share in the same period last year [1] - The consensus estimate for quarterly revenue is $8.9 billion, up from $8.29 billion reported last year [1] - Needham analyst Mike Matson upgraded Medtronic from Hold to Buy, setting a price target of $121 [1] Dividend Information - Medtronic currently offers an annual dividend yield of 2.82%, translating to a quarterly dividend of 71 cents per share, or $2.84 annually [2] - To generate $500 monthly or $6,000 annually from dividends, an investment of approximately $213,159 or around 2,113 shares is required [2] - For a more modest income of $100 per month or $1,200 annually, an investment of $42,672 or around 423 shares is needed [2] Dividend Yield Dynamics - Dividend yield can fluctuate based on changes in both the dividend payment and the stock price [3] - For instance, if a stock with a $2 annual dividend is priced at $50, the yield is 4%, but if the price rises to $60, the yield drops to 3.33% [4] - Conversely, if the stock price falls to $40, the yield increases to 5% [4] - Changes in dividend payments also affect yield; an increase in dividends raises yield if the stock price remains constant [5] Stock Performance - Medtronic's shares fell by 0.2%, closing at $100.88 on Thursday [5]

Earnings Report - Medtronic plc is set to release its third-quarter earnings on February 17, with analysts expecting earnings of $1.34 per share, a decrease from $1.39 per share in the same period last year [1] - The consensus estimate for quarterly revenue is $8.9 billion, up from $8.29 billion reported last year [1] - Needham analyst Mike Matson upgraded Medtronic from Hold to Buy, setting a price target of $121 [1] Dividend Information - Medtronic currently offers an annual dividend yield of 2.82%, translating to a quarterly dividend of 71 cents per share, or $2.84 annually [2] - To generate $500 monthly or $6,000 annually from dividends, an investment of approximately $213,159 or around 2,113 shares is required [2] - For a more modest income of $100 per month or $1,200 annually, an investment of $42,672 or around 423 shares is needed [2] Dividend Yield Dynamics - Dividend yield can fluctuate based on changes in both the dividend payment and the stock price [3] - For instance, if a stock with a $2 annual dividend is priced at $50, the yield is 4%, but if the price rises to $60, the yield drops to 3.33% [4] - Conversely, if the stock price falls to $40, the yield increases to 5% [4] Impact of Dividend Changes - Changes in dividend payments directly affect the yield; an increase in dividends raises the yield if the stock price remains constant, while a decrease lowers it [5] - Medtronic's shares fell by 0.2% to close at $100.88 on Thursday [5]

Core Viewpoint - The Jiangsu Medical Device Technology Industrial Park, Medpark, is experiencing significant growth and innovation, positioning itself as a key player in the high-end medical device industry, with a focus on research, production, and sales [1][10]. Group 1: Innovation and Development - The park has seen the signing of major projects, such as the headquarters of Shangmei Medical Group, which aims to create a comprehensive base for research, production, and sales [1]. - Numerous products from the park have been included in Jiangsu Province's innovative medical device catalog, showcasing the park's commitment to innovation [1]. - Companies like Suzhou Langmu Medical Technology are developing groundbreaking products, such as a micro-invasive glaucoma stent, which addresses a significant clinical need in China [2]. Group 2: Achievements and Recognition - The park has achieved notable milestones, including the establishment of national standards for wearable brain-machine interface products and the approval of various medical devices by the FDA [3][4]. - Medpark has been recognized with multiple awards, including being named a top 30 most vibrant biopharmaceutical industrial park in China [4]. Group 3: Support and Services - Medpark offers a comprehensive public service system, including high-level research institutions and a unique high-end medical device technology innovation center, which supports companies in their development processes [5][6]. - The park has implemented a "2+5+N" service system, providing tailored support for companies at various stages of development, including financial and legal services [8][9]. Group 4: Market Potential and Future Outlook - The medical device industry is characterized as a "sunrise industry," with significant growth potential driven by innovation and technological advancements [1][10]. - The park aims to accelerate its growth towards becoming a billion-level medical device industry base, leveraging its resources and services to support enterprise development [1][10].

Core Viewpoint - Medtronic plc will announce its financial results for the third quarter of fiscal year 2026 on February 17, 2026, following the end of the quarter on January 23, 2026 [1] Group 1: Financial Reporting - A video webcast discussing the financial results will begin at 7:00 a.m. CST on the announcement day [1] - A news release containing summary financial information will be issued at approximately 5:45 a.m. CST [1] - A replay and transcript of the prepared remarks will be available within 24 hours of the webcast [1] Group 2: Company Overview - Medtronic is headquartered in Galway, Ireland, and is a leading global healthcare technology company [1] - The company employs over 95,000 people across more than 150 countries and addresses 70 health conditions with its technologies and therapies [1] - Medtronic's mission is to alleviate pain, restore health, and extend life, focusing on innovative solutions in various medical fields [1]